FDA approves Medtronic device for sealing off deeper, smaller brain aneurysms

Migraine headache/epilepsy brain image
The new indication includes small or medium aneurysms, through to the end of the brain's carotid artery. (CC0 Creative Commons)

Medtronic has received approval of an expanded indication from the FDA for its Pipeline Flex embolization device, for patients with smaller aneurysms found deeper in the brain.

The system was previously approved for endovascular treatment with large or giant, wide-necked intracranial aneurysms, located in the internal carotid artery from the petrous to the superior hypophyseal segments.

The new indication includes patients with small or medium brain aneurysms, from the petrous through to the terminus of the internal carotid artery, in parent blood vessels measuring between 2 mm and 5 mm in diameter.

Webinar

How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC

CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.

The device is designed to divert blood away from an aneurysm, using a braided, cylindrical mesh tube implanted across the base of the aneurysm, to help reconstruct the damaged section of the blood vessel.

Medtronic's Pipeline Flex system

RELATED: Using genomics and machine learning to predict aneurysm risk

Its approval was based on a clinical study of 141 patients with an average aneurysm size of 5 millimeters. The study’s one-year occlusion rate reached 76.7%, with a 2.2% occurrence of major stroke or neurological death.

The device was originally approved after a five-year study of large or giant aneurysms, demonstrating efficacy rates from 70.8% at one year, to 95% after five years, with no documented cases of recurrence, according to Medtronic.

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

The FDA has cleared its first fully disposable duodenoscope, following years of reports of infections being transmitted between patients.

OR-focused AI provider Caresyntax has garnered $45.6 million in new funding and picked up a data analytics firm to broaden its footprint.